Kim D. Blickenstaff

This profile gathers the share dealings of Kim D. Blickenstaff across 6 companies, led by Tandem Diabetes Care Inc, Dexcom Inc and Medivation, Inc. Between 28 November 2005 and 21 November 2024, the trades on record add up to 190 filings.

Market trades split into 5 purchases (€6.2M) and 128 sales (€142.1M). Taken together, the sales exceed the purchases by €135.8M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 6 share grants and 35 option exercises. In 2024 alone, the filings show 1 purchase and 2 sales.

In size, the median ticket on the buying side is €1.2M. On 1 out of 4 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

On 22 November 2024 came the latest disclosure, an open-market sale for €893k in Tandem Diabetes Care Inc. The most recent open-market purchase was published on 13 June 2024, 863 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.